Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas

PURPOSE: Neurofibromatosis type 2 (NF2) is a tumor predisposition syndrome characterized by bilateral vestibular schwannomas (VSs) resulting in deafness and brainstem compression. This study evaluated efficacy and biomarkers of bevacizumab activity for NF2-associated progressive and symptomatic VSs....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Blakeley, Jaishri O., Ye, Xiaobu, Duda, Dan G., Halpin, Chris F., Bergner, Amanda L., Muzikansky, Alona, Merker, Vanessa L., Gerstner, Elizabeth R., Fayad, Laura M., Ahlawat, Shivani, Jacobs, Michael A., Jain, Rakesh K., Zalewski, Christopher, Dombi, Eva, Widemann, Brigitte C., Plotkin, Scott R.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2016
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4872317/
https://ncbi.nlm.nih.gov/pubmed/26976425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.3817
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky